Core Viewpoint - The article discusses a groundbreaking technology called "liquid droplet printing," developed by a team led by researcher Song Yanlin at the Chinese Academy of Sciences, which allows for the precise attachment of ultra-thin electronic membranes to complex biological surfaces using a droplet of water as a medium [1][2]. Group 1: Technology Overview - The "liquid droplet printing" technology enables the attachment of flexible electronic devices to irregular surfaces such as human skin, nerves, and the brain without damaging the delicate membranes [2][3]. - The process utilizes a droplet of water to pick up the ultra-thin membrane and release it onto the target surface, acting as both a facilitator for adhesion and a lubricant to prevent stress-related damage during application [2][5]. Group 2: Experimental Results - Experiments demonstrated that even a gold film with a thickness of only 150 nanometers could be successfully attached to complex structures like paramecium, dandelion fluff, and shell textures using this technology [5]. - In live experiments, silicon-based electronic membranes were printed onto the sciatic nerve and cerebral cortex of mice, achieving a non-destructive and conformal attachment that allowed for the conversion of light signals into electrical signals, successfully stimulating nerve activity [5]. Group 3: Future Prospects - This technology breaks the limitations of traditional flexible electronic device attachment and has broad application potential in fields such as brain-machine interfaces, neural regulation, and wearable devices, with possible extensions to tissue engineering and smart displays [6]. - The innovation is likened to the impact of printing technology on human civilization, suggesting that "liquid droplet printing" could revolutionize the preparation and attachment of electronic devices, making it as easy as applying a screen protector [6].

Industry Overview - Regenerative medicine (RM) utilizes biological and engineering theories to promote self-repair and regeneration of the body, or to construct new tissues and organs for repairing, regenerating, and replacing damaged tissues and organs [1][4] - The global regenerative medicine market is expanding, with the market size projected to grow from $20.04 billion in 2021 to $35.82 billion in 2024 [1][12] Market Status - Regenerative medicine is considered the "third medical revolution" following drug and surgical treatments, becoming a core component of life science strategies globally [6][12] - The industry includes upstream raw materials and equipment supply, midstream product R&D and production, and downstream application through medical institutions and aesthetic organizations [4][12] Policy and Regulatory Environment - Various countries have implemented policies to promote the development of regenerative medicine, such as the U.S. "21st Century Cures Act" and the EU's regulations on biotechnology [7][9] - In China, policies have been established to support the clinical application of regenerative medicine technologies, including the management of stem cell therapies and the promotion of innovative medical technologies [9][23] Market Competition - The regenerative medicine sector has attracted numerous companies, with major players including Johnson & Johnson, Bard, Geistlich, and domestic firms like Zhenghai Biological, Guanhou Biological, and Maipu Medical [16][18] - The market is characterized by a diverse range of products and applications, with companies focusing on specific therapeutic areas such as cancer treatment, tissue repair, and organ transplantation [18][20] Development Trends - The industry is witnessing technological integration and innovation, with advancements in 3D bioprinting, gene editing, and artificial intelligence enhancing treatment efficacy [22][24] - The dual drive of policy support and capital investment is accelerating the commercialization of regenerative medicine, with increasing coverage of medical insurance for regenerative products [23][24]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 随着全球科技的不断进步，医疗器械创新的步伐也在加快。根据美国的统计数据， 70%的医疗器械创新想法 都来自于临床医生的实际经验和需求 。临床医 生不仅是治疗的执行者，也是医疗器械创新的重要推动者。 过去，许多一线城市的三甲医院的大专家们已经走在了创新的前沿，取得了显著的成果转化。而在更为广泛的地区，比如像东北地区，医工交叉仍然处于一 个萌芽阶段，充满了探索的机会与挑战。 亓明教授，作为大连医科大学附属第一医院血管外科的资深专家，正是这种医工交叉领域探索的代表之一 。思宇 MedTech记者近日专访了亓教授，探讨了他在这一领域的深刻思考与实践。 在血管外科工作超过20年的亓明教授，近年来开始逐渐对医工交叉领域产生了浓厚兴趣。对于他来说，这一转变并非偶然，而是基于长期的临床积累以及对 创新医疗器械需求的深刻理解。 一、为什么开始关注医工交叉？ 亓教授坦言，自己对医工交叉的兴趣源自三个主要原因。 第一，看到许多大专家们已经在尝试这个领域。 "最早，我接触临床时 ...